首页> 外文期刊>Pediatric Pulmonology >Efficacy of early piston-type high-frequency oscillatory ventilation in infants with respiratory distress syndrome.
【24h】

Efficacy of early piston-type high-frequency oscillatory ventilation in infants with respiratory distress syndrome.

机译:早期活塞型高频振荡通气对呼吸窘迫综合征婴儿的疗效。

获取原文
获取原文并翻译 | 示例
       

摘要

We investigated whether the combination of surfactant replacement therapy and early application of high-frequency oscillatory ventilation (HFOV) was more effective in patients with respiratory distress syndrome (RDS) than late application of HFOV and conventional mechanical ventilation (CMV). To determine this, we retrospectively reviewed the cases of 126 neonates with RDS who received surfactant replacement therapy within 4 hr after birth. Patients were grouped into those who received HFOV immediately after birth (HFOV group), those who initially were ventilated by CMV and subsequently received HFOV (CMV/HFOV group), and those who did not receive HFOV (CMV group). Changes in respiratory system compliance (Crs), arterial-alveolar oxygen gradient (a/ApO(2)), and mean airway pressure (MAP) were compared. Infants who received HFOV were less mature than those who received CMV. The a/ApO(2) measured immediately after birth before surfactant replacement therapy was significantly lower in the HFOV and CMV/HFOV group than in the CMV group. After 72 hr, the Crs in the HFOV group was higher than in any other group and was significantly higher than the CMV/HFOV group at 48 and 120 hr. These results suggest that initiating HFOV in combination with surfactant replacement therapy immediately after birth provides effective ventilatory support for infants with RDS. Copyright 2001 Wiley-Liss, Inc.
机译:我们调查了表面活性剂替代疗法和早期使用高频振荡通气(HFOV)的组合是否比晚期应用HFOV和常规机械通气(CMV)的呼吸窘迫综合征(RDS)患者更有效。为了确定这一点,我们回顾了126例RDS新生儿的病例,这些新生儿在出生后4小时内接受了表面活性剂替代治疗。患者分为出生后立即接受HFOV的患者(HFOV组),最初接受CMV通气,随后接受HFOV的患者(CMV / HFOV组)和不接受HFOV的患者(CMV组)。比较了呼吸系统顺应性(Crs),动脉-肺泡氧梯度(a / ApO(2))和平均气道压力(MAP)的变化。接受HFOV的婴儿不如接受CMV的婴儿成熟。 HFOV和CMV / HFOV组出生后立即进行表面活性剂替代治疗之前测得的a / ApO(2)显着低于CMV组。 72小时后,HFOV组中的Crs高于其他任何组,并且在48和120小时时显着高于CMV / HFOV组。这些结果表明,出生后立即开始HFOV联合表面活性剂替代治疗可为RDS婴儿提供有效的通气支持。版权所有2001 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号